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Abstract
Background: Hydrarthrosis, which is associated with knee pain and limited range of motion, decreases the quality
of life (QOL) of patients with osteoarthritis (OA). The Kampo medicine boiogito is prescribed for the treatment of
knee OA with hydrarthrosis; however, its precise mechanisms of action remain unknown. The purposes of this study
were to assess the pharmacological effects of boiogito and its mechanisms of action on joint effusion in rats with
surgically induced OA.
Methods: A rat OA model was produced by transecting the anterior (cranial) cruciate ligament, medial collateral
ligament, and medial meniscus in the right knee joints of 7-week-old female Wistar rats. The rats were given chow
containing boiogito (1 or 2 %) or indomethacin (0.002 %) for 4 weeks after surgical transection. Levels of interleukin-1β
(IL-1β) and hyaluronic acid (HA) were measured by enzyme-linked immunosorbent assay. Knee joint pain was assessed
using an incapacitance tester. Osmotic water permeability in cultured rabbit synovial cells was assessed using
stopped-flow analysis.
Results: Increased synovial fluid volume and knee joint pain were observed in rats with surgically induced OA.
In rats with OA, levels of IL-1β and HA in the articular cavity were higher but concentration of HA in synovial fluid
was lower than in sham-operated rats, suggesting excessive synovial fluid secretion. Administration of boiogito
improved hydrarthrosis, IL-1β, and HA concentrations and alleviated knee joint pain in rats with OA. Indomethacin
reduced IL-1β and knee joint pain but failed to improve hydrarthrosis or HA concentration in rats with OA. Osmotic
water permeability in synovial cells, which is related to the function of the water channel aquaporin, was decreased by
treatment with boiogito.
Conclusion: Boiogito ameliorates the increased knee joint effusion in rats with OA by suppressing pro-inflammatory
cytokine IL-1β production in the articular cavity and regulating function of water transport in the synovium. The
improvement of hydrarthrosis by boiogito results in the increased HA concentration in synovial fluid, thus reducing
joint pain. Boiogito may be a clinically useful treatment of QOL in patients with OA with hydrarthrosis.
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Background
Osteoarthritis, which is characterized by inflammation
and degradation of the cartilage matrix, is triggered
mainly by excessive joint forces and leads to pathological
changes in the joints. Knee OA is a common problem in
older women who complain of joint pain [1]. Nonsteroi-
dal anti-inflammatory drugs are widely used as an effect-
ive and conservative treatment for knee OA. However,
serious problems such as gastrointestinal tract adverse
events result from long-term NSAID use [2]. Mean-
while, the intra-articular injection of HA, especially
high-molecular-weight HA, has been shown to main-
tain the cartilage matrix and minimize inflammation by
lubricating and cushioning joints. However, its use car-
ries the risk of local adverse events including effusions
or flares [3, 4].
Hydrarthrosis is associated with pain and limitation in
the range of knee motion; these are critical clinical symp-
toms of OA. It is caused predominantly by synovial in-
flammation, which is mediated by cytokines such as IL-1β
[5]. In addition, AQP is a water channel and maintains
body water homeostasis. Some AQP isoform expressions
are increased in the articular joints of patients with OA
and rheumatoid arthritis, suggesting the relevance of
hydrarthrosis [6, 7]. Synovial fluid aspiration is commonly
performed as a palliative therapy for hydrarthrosis.
Boiogito, a traditional Japanese herbal (Kampo) medicine,
is prescribed as a remedy for arthritis, nephrosis, edema,
hyperhidrosis, and obesity. In particular, it is effective for
these diseases in patients with the symptoms of fatigue,
light-complexion, and soft-muscle. The usual adult dose is
7.5 g/day orally divided over two or three doses before or
between meals. The dosage may be adjusted according to
the patient’s age and body weight and symptoms [8]. Boio-
gito is an extract composed of six herbal drugs included
Sinomenium Stem and Astragalus Root. Sinomenine, a in-
gredient extracted from the Sinomenium Stem, has demon-
strated potential anti-inflammatory activity. In vitro studies
have shown that sinomenine inhibit lymphocyte prolifera-
tion [9, 10] and decreased eicosanoid synthesis and nitric
oxide production of macrophages [11]. In rat adjuvant- and
collagen-induced arthritis, sinomenine treatment improved
arthritic score and hind paw swelling [12]. Astragalus Root
also has anti-inflammatory activity through decreasing pro-
duction of cytokine, Interferon-γ or Tumor necrosis factor-
α in a rat model of autoimmune myocarditis, in NC/Nga
mice and in db/db diabetic mice [13–15]. These reports
suggest boiogito have also possibility for decreasing inflam-
mation such as osteoarthritis. A recent clinical study [16]
demonstrated that oral administration of boiogito is a pos-
sible treatment for knee joint effusion in OA patients and
has no severe adverse effects; however, its mechanisms re-
main unknown. In this study, we examined the effect of
boiogito on hydrarthrosis and its mechanism of action
using a rat model of surgically induced OA and cultured
synovial cells.
Methods
Surgically induced OA animal model
Female Wistar rats were purchased from Japan Charles
River Laboratory (Tokyo, Japan) and housed in a regu-
lated environment. Standard laboratory chow and water
were available ad libitum. All experimental procedures
were performed according to the “Guidelines for the
Care and Use of Laboratory Animals” and approved by
the Laboratory Animal Committee of Tsumura & Co.
(Tokyo, Japan).
Seven-week-old rats were anesthetized with intraperi-
toneal injections of sodium pentobarbital, and surgical
sites were shaved. The right knee joint of each rat was
exposed; the medial collateral and anterior (cranial) cru-
ciate ligaments were transected and the medial meniscus
was resected using a microsurgical knife. In the sham-
operated rats (n = 8), the right knee joint was exposed
and then closed.
Drug treatment
The Kampo medicine boiogito was obtained by Tsumura
& Co. (Tokyo, Japan). Boiogito is a powdered extract pro-
duced under stringent manufacturing practices by spray
drying a hot-water extract of the herbal mixture, which is
composed of the following six Japanese Pharmacopoeia
standard herbal constituents in fixed proportions: Sinome-
nium Stem (Sinomeni Caulis et Rhizoma) 5.0 g/18.5 g, As-
tragalus Root (Astragali Radix) 5.0 g/18.5 g, Atractylodes
Lancea Rhizoma (Atractylodis Lanceae Rhizoma) 3.0 g/
18.5 g, Jujube (Zizyphi Fructus) 3.0 g/18.5 g, Glycyrrhiza
(Glycyrrhizae Radix) 1.5 g/18.5 g, and Ginger (Zingiberis
Rhizoma) 1.0 g/18.5 g. Kampo medicines, including
boiogito, are standardized with respect to the quality
and quantity of ingredients and are prescribed for the
treatment of several diseases under the oversight of the
Japanese Ministry of Health, Labour and Welfare. A
three-dimensional high-performance liquid chromatog-
raphy profile of boiogito provided by Tsumura & Co. is
shown in Fig. 1. Numerous major ingredients included
in boiogito are identified.
The rats with OA were given chow containing boiogito
(1 or 2 %, n = 12), indomethacin (0.002 %, n = 11; Sigma,
St. Louis, MO, USA), or control chow (n = 12). The mean
daily doses of 1 and 2 % boiogito and indomethacin were
0.73 g/kg, 1.49 g/kg, and 1.48 mg/kg, respectively. The as-
says and tests described below were conducted 4 weeks
after surgery.
Incapacitance test
Weight-bearing changes in the rats with OA were measured
using an incapacitance tester [17]. Postural imbalance,
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which reportedly indicates a change in the pain threshold
and weight distribution of the limbs, was decreased. Each
rat stood on its hind limbs on the incapacitance apparatus,
and the weight borne by each hind limb was measured for
5 s. The ratio of the weight borne by the right to left hind
limb was calculated. The mean of 10 consecutive mea-
surements for each rat was recorded.
Analytical assays
After the rats were sacrificed, synovial fluid in the articular
cavity was collected using filter paper, and fluid volume
was estimated by weight. The synovial fluid samples were
eluted from the filter paper by immersion in 250 μL of
stirred ice-cold PBS for 10 min. The levels of HA (Hyalur-
onan Assay Kit; Seikagaku Co., Tokyo, Japan) and IL-1β
(Bio-Plex; Bio-Rad, Hercules, CA, USA) in the synovial
fluid samples were measured by enzyme-linked immuno-
sorbent assay. HA concentration was calculated by divid-
ing HA level by fluid volume.
Gene expression assay
Synovial membrane gene expression levels were mea-
sured using a real-time polymerase chain reaction sys-
tem (ABI 7900HT; Applied Biosystems, CA, USA). Total
RNA was extracted from the synovial membrane sam-
ples, which were collected after the rats were sacrificed,
using an RNeasy Mini Kit, and DNA was removed from
RNA using RNase-Free DNase (Qiagen, Valencia, CA,
USA). Reverse transcription reactions were performed
using a TaqMan reverse transcription kit (Applied Bio-
systems). All oligonucleotide primers and fluorogenic
probe sets for TaqMan real-time PCR were obtained
from Applied Biosystems; these included matrix
metalloprotease 3 (MMP3; Rn00591740_m1), hyalur-
onan synthase 2 (HAS2; Rn00565774_m1), hyaluronidase
1 (HYAL1; Rn02133715_s1), and aquaporin 1 (AQP1;
Rn00562834_m1). Beta actin (ACTB; Rn00667869_m1)
was used as an endogenous control.
Histochemical study
Articular cartilage was collected after the rats were sacri-
ficed. It was fixed in 15 % phosphate-buffered formalin,
decalcified and embedded in paraffin. Histologic sections
4 μm in thickness were stained with Safranin O for light
microscopic examination. Modified Mankin scores were
obtained using a semi-quantitative pathological scoring
system: Structure (0, normal; 1, surface irregularities; 2,
pannus and surface irregularities; 3, clefts within the
Fig. 1 A three-dimensional high-performance liquid chromatography profile of boiogito, provided by Tsumura & Co
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transitional zone; 4, clefts within the radial zone; 5, clefts
within the calcified zone; and 6, complete disorganization),
Cell (0, normal; 1, diffuse hypercellularity; 2, cloning; and 3,
hypocellularity), and Safranin O staining (0, normal; 1,
slight reduction; 2, moderate reduction; 3, severe reduction;
and 4, no dye noted).
Osmotic water permeability in synovial cells
Osmotic water permeability was assessed using a stopped-
flow analysis [18]. Rabbit synovial cells (HIG-82 [ATCC
CRL-1832]; ATCC, Manassas, VA, USA) were cultured in
10 % fetal bovine serum in Hams’ F12 medium. Cells were
incubated in the medium for 90–100 min after detach-
ment with trypsin/EDTA and placed in ice-cold PBS. The
cell suspensions (106 cells/mL) were rapidly mixed with
equal volumes of 600 mmol/L mannitol-containing PBS at
10 °C using a stopped-flow apparatus (SX18MV-R; Ap-
plied Photophysics Ltd., Leatherhead, Surrey, UK). They
were then illuminated by a 400-nm light, and the light
scattering was measured for 5 s. The scattered light inten-
sity was fit to a single exponential curve of 1.5 s, and the
osmotic water permeability was calculated using the fol-
lowing equation:
Pf cm=sð Þ ¼ d V=V0ð Þ=dt½ = Vw  SAV  dOSM½ ;
where Pf is the osmotic water permeability, d(V/V0)/dt
is the initial curve slope, Vw (cm3/mol) is the molar ratio
of water, SAV (cm-1) is the surface area to the initial cell
Fig. 2 Effects of boiogito and indomethacin on hydrarthrosis in a rat
model of knee osteoarthritis (OA). Rats with OA were given chow
containing boiogito (1 or 2 %, n = 12) or indomethacin (Ind; 0.002 %,
n = 11) for 4 weeks. Increased synovial fluid volume and interleukin-1β
in the articular cavity were observed in rats with surgically induced OA.
a: Synovial fluid volume in rats with OA was decreased by boiogito.
b: The level of interleukin-1β in the articular cavity in rats with OA was
reduced by boiogito and Ind. Results are expressed as mean ± standard
error (SE). ##P < 0.01 vs. sham-operated rats (Sham, n = 8), *P < 0.05,
**P < 0.01 vs. non-treated control rats with OA (Con, n = 12)
Fig. 3 Effects of boiogito and indomethacin on hyaluronic acid (HA)
in a rat model of knee osteoarthritis (OA). The contents of HA in the
articular cavity (a) were increased but HA concentrations in the
synovial fluid (b) were decreased in rats with OA (Con, n = 12)
compared with those in sham-operated rats (Sham, n = 8). Daily
administration of boiogito (2 %, n = 12) did not change the HA content
but recovered the decreased HA concentration in synovial fluid. These
parameters were not influenced by indomethacin (Ind, n = 11).
Results are expressed as mean ± SE. ##P < 0.01 vs. Sham, **P < 0.01 vs.
non-treated control rats with OA (Con)
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volume, and dOSM (mol/cm3) is the osmolality of the
extracellular solution.
Boiogito and the extracts of its six constituents were
dissolved in a solution of 5 % dimethylsulfoxide in PBS
and centrifuged for 5 min at 10,000 rpm. The superna-
tants (0.1 mL) were added to the cell suspension and
600 mmol/L of mannitol-containing PBS (final volume,
1 mL). Osmotic water permeability activity was exam-
ined 15 min after the reaction. The AQP inhibitor mer-
curic chloride was assayed as a positive control.
Statistical analysis
Values for individual groups are shown as mean ± stand-
ard error (SE). To assess differences among groups, the
Student t-test, a multi-group Dunnett test, or the Steel
test was performed. Values of P < 0.05 were considered
statistically significant.
Results
Surgically induced OA model
Increased synovial fluid volume was observed in rats
with OA. Daily administration of boiogito, but not indo-
methacin, significantly decreased the synovial fluid vol-
ume in rats with OA (Fig. 2a). IL-1β levels in the
articular cavity were approximately three times higher in
rats with OA than in sham-operated rats. Both boiogito
and indomethacin were associated with decreased IL-1β
levels in rats with OA (Fig. 2b).
In rats with OA, the total content of HA in the articu-
lar cavity was increased (Fig. 3a) but the concentration
of HA in the synovial fluid was decreased (Fig. 3b) com-
pared with measurements in sham-operated rats. After
Fig. 4 Effects of boiogito and indomethacin on gene expressions in the synovial membranes in a rat model of knee osteoarthritis (OA). Data are
shown as the relative mRNA expression of matrix metalloprotease 3 (MMP3; a), hyaluronan synthase 2 (HAS2; b), hyaluronidase 1 (HYAL1; c) and
aquaporin 1 (AQP1; d), normalized to reference gene of beta actin (ACTB). The expressions of MMP3 (a) and HAS2 (b) increased and that of HYAL1 (c)
decreased in the synovial membranes of rats with OA (Con, n = 12) compared with those of sham-operated rats (Sham, n = 8). Expressions of these
genes were not influenced by boiogito (n = 12). Indomethacin (Ind, n = 11) decreased HAS2 mRNA and slightly increased AQP1 mRNA in the synovial
membranes of rats with OA. Results are expressed as mean ± SE. ##P < 0.01 vs. Sham, *P < 0.05, **P < 0.01 vs. non-treated control rats with OA (Con)
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daily administration of boiogito, there was no change in
the HA content in the articular cavity, but the HA con-
centration in the synovial fluid had increased.
The gene expressions of MMP3 (Fig. 4a) and HAS2
(Fig. 4b) increased in the synovial membranes of rats
with OA, whereas that of HYAL1 (Fig. 4c) decreased.
AQP1 expressions (Fig. 4d) were not significantly dif-
ferent between rats with OA and sham-operated rats.
Expressions of these genes were not influenced by
boiogito. Indomethacin administration inhibited the
increased HAS2 expression and slightly increased the
AQP1 expression.
Rats with OA showed weight-bearing deficits, most
likely caused by knee joint pain. Boiogito and indometh-
acin were associated with significantly improved weight-
bearing ratios in rats with OA (Fig. 5).
Cartilage surface irregularities, diffuse hypercellularity,
and decreased Safranin O staining were observed in joints
of rats with OA 4 weeks after surgery. Daily administra-
tion of boiogito tended to alleviate the histochemical
changes in articular cartilage of rats with OA (Additional
file 1: Figure S1). Mankin score in OA rats decreased after
treatment with boiogito, but not significantly (Control:
3.8 ± 0.4; Boiogito (1 %): 3.0 ± 0.9; Boiogito (2 %): 2.6 ± 0.9;
Indomethacin: 3.1 ± 1.1).
Osmotic water permeability in synovial cells
Boiogito (0.25–1 mg/mL) and the AQP inhibitor mer-
curic chloride (10 μmol/L) inhibited osmotic water per-
meability in the synovial cells (Fig. 6a). We examined
the effect of the six boiogito constituents (0.5 mg/mL)
and found that Sinomenium Stem showed a dose-
dependent decrease in osmotic water permeability in the
synovial cells (Fig. 6b, c).
Discussion
We found that the Kampo medicine boiogito attenuated
hydrarthrosis and joint pain and decreased IL-1β in the ar-
ticular cavity in rats with surgically induced OA. Synovial
tissue inflammation is known to be a pathogenic factor of
OA of the knee. Several cytokines cause increased joint in-
flammation, particularly the pro-inflammatory cytokine
IL-1β is most frequently detected in synovial tissues of OA
patients [5]. Additionally, plasma levels of interleukin-1 re-
ceptor antagonist (IL1Ra) are modestly associated with the
severity and progression of symptomatic knee OA [19].
Several reports have shown that IL-1β produces matrix
metalloprotease, which degrade the cartilage matrix, in
chondrocytes and synoviocytes [20–22]. We also demon-
strated that intra-articular injections of IL-1β increased
synovial fluid volume and the expression of MMP3 in the
synovial membrane in rats (data not shown). In this study,
increased IL-1β in the articular cavity and expression of
MMP3 in the synovial membrane were observed in rats
with OA. Boiogito decreased IL-1β, but not MMP3, in rats
with OA. These results suggest that the inhibitory effect of
boiogito on knee hydrarthrosis in rats with OA is mediated
by the suppression of pro-inflammatory cytokine IL-1β
production in the articular cavity. Sinomenine, a principal
component of boiogito, has demonstrated potential anti-
inflammatory activity [10]. In animal models of adjuvant-
and collagen-induced arthritis, sinomenine improved
symptoms and decreased tumor necrosis factor-α and
IL-1β expressions. It was also shown to be involved in
inhibiting nuclear factor-κB binding activity by upregu-
lating IκB-α expression [12, 23]. Sinomenine may play a
important role in improving hydrarthrosis in rats with
OA in this study.
On the other hand, indomethacin decreased IL-1β in
the articular cavity as well as boiogito but failed to inhibit
joint effusion in rats with OA. These findings suggest that
a decrease in IL-1β is necessary but insufficient for the im-
provement of hydrarthrosis. Water transport is a physiolo-
gically important system for maintaining body water
homeostasis. AQPs are specific protein channels for water
transport, and some AQP isoforms (AQP1, AQP3, and
AQP9) are located in synovial microvessels, synoviocytes,
and chondrocytes [24]. Immunohistochemistry revealed
increased AQP1 expression in the articular joints of pa-
tients with rheumatoid arthritis, suggesting a potential
role for synovial AQP1 in joint swelling, vasogenic syn-
ovial fluid formation, and hydrarthrosis associated with
synovial inflammation [6, 25]. In the present study, the
AQP1 gene expression in the synovial membrane was not
influenced by OA induction or boiogito treatment but
Fig. 5 Effects of boiogito and indomethacin on joint pain in a rat model
of knee osteoarthritis (OA). Joint pain was assessed by the weight ratio of
the right (osteoarthritic) to left (contralateral control) hind limbs using an
incapacitance tester. Rats with OA showed weight-bearing deficits
associated with knee pain. Boiogito (n= 12) and indomethacin (n= 11)
significantly alleviated weight-bearing deficits in rats with OA. Results are
expressed as mean ± SE. ##P< 0.01 vs. sham-operated rats (Sham, n= 8),
*P< 0.05, **P< 0.01 vs. non-treated control rats with OA (Con, n= 12)
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slightly increased by indomethacin treatment. To assess
the function of AQPs in synovial cells, we performed
the stopped-flow analysis in vitro. The osmotic water
permeability of the synovial cells was inhibited by boio-
gito and the AQP inhibitor mercuric chloride. These
findings suggest that the inhibitory effect of boiogito on
water transport in synovial cells, which seems to be me-
diated by AQPs, may be partially related to a decrease
in joint effusion in rats with OA. Sinomenium Stem,
one of the constituents of boiogito, also inhibited the
osmotic water permeability of the synovial cells. How-
ever, the effect of Sinomenium Stem is insufficient to
completely explain the effect of boiogito, which is pos-
sibly associated with the synergistic effect of other con-
stituents. Future experiments will determine whether
ingredients of boiogito have an AQP-mediated effect
on hydrarthrosis.
HA in synovial fluid plays an important role in main-
taining high fluid viscosity and preserving the normal
cartilaginous matrix by lubricating and cushioning the
joint [3]. A reduced concentration of HA is critical to
cartilage disorder progression in OA. Decreased HA
concentrations in synovial fluid were noted in rats with
surgically induced OA. However, the total HA content
of the articular cavity increased in rats with OA. This
process is mediated by increased HAS2 and decreased
HYAL1 in the synovial membrane, suggesting that HA
production is accelerated in arthritis. Therefore, ex-
cessive hydrarthrosis appears to reduce HA concentra-
tions in the synovial fluid of rats with OA. Daily
administration of boiogito recovered the decreased
HA concentration in the synovial fluid without chan-
ging the HA content of the articular cavity in rats with
OA. These findings suggest that boiogito maintains
the HA concentration by inhibiting joint effusion. The
effect of boiogito on HA concentration appears to re-
sult in lubricating and cushioning the joint, thus redu-
cing joint pain.
Fig. 6 Effect of boiogito on water permeability in cultured synovial cells. a Boiogito (0.25–1 mg/mL) and the aquaporin inhibitor mercuric
chloride (10 μmol/L) inhibited water permeability in synovial cells (n = 8–9). b, c Sinomenium Stem, one of six boiogito constituents, decreased
water permeability of the synovial cells (n = 4–5) in a dose-dependent manner (n = 4–6). Results are expressed as mean ± SE. *P < 0.05, **P < 0.01
vs. vehicle
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Conclusions
Our study demonstrated that the Kampo medicine boio-
gito improves hydrarthrosis, resulting in an increased HA
concentration in the synovial fluid and alleviation of knee
joint pain in rats with surgically induced OA. Boiogito ap-
pears to alleviate hydrarthrosis by suppressing articular
pro-inflammatory cytokine IL-1β production and inhibit-
ing water transport through AQPs in the synovium. Boio-
gito may be a clinically useful treatment of frequent
hydrarthrosis, which is associated with pain and limited
range of motion in the knees of patients with OA.
Additional file
Additional file 1: Figure S1. Histochemical changes in joints of rats
with osteoarthritis. Cartilage surface irregularities, diffuse hypercellularity,
and decreased Safranin O staining were seen in joints of rats with OA 4
weeks after surgery. Daily administration of boiogito and indomethacin
partially tended to alleviate the histochemical changes in articular
cartilage of rats with OA. (PDF 250 kb)
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